FAIRNESS ALERT: Rosen Law Firm Encourages Spero Therapeutics, Inc. Investors Suffering Losses to Find Counsel Ahead of Important Deadline in Securities Class Action – SPRO | New

0

NEW YORK–(BUSINESS WIRE)–May 27, 2022–

WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Spero Therapeutics, Inc. (NASDAQ: SPRO) securities between October 28, 2021 and October 2, 2021. May 2022, both dates inclusive (the “Class Period”). If you wish to act as lead plaintiff, you must move the Court no later than July 25, 2022.

SO WHAT: If you purchased securities of Spero Therapeutics during the Class Period, you may be entitled to compensation without payment of any disbursements or fees through a contingency fee arrangement.

WHAT TO DO NEXT: To join the Spero Therapeutics class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for class action information. A class action lawsuit has already been filed. If you wish to act as lead plaintiff, you must move the Court no later than July 25, 2022. A lead plaintiff is a representative party acting on behalf of the other class members to direct the litigation.

WHY THE ROSEN LAW: We encourage investors to select qualified attorneys with proven track records in leadership roles. Often, companies issuing reviews do not have comparable experience, resources, or significant peer recognition. Be wise in choosing lawyers. Rosen Law Firm represents investors worldwide, focusing its practice on securities class action and shareholder derivative litigation. Rosen Law Firm has reached the largest securities class action settlement against a Chinese company. Rosen Law Firm was ranked #1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has ranked in the top 4 every year since 2013 and has recovered hundreds of million dollars for investors. In 2019 alone, the company secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs’ Bar. Many of the firm’s attorneys have been recognized by Lawdragon and Super Lawyers.

CASE DETAILS: According to the lawsuit, the defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) the data submitted in support of the New Drug Application ( “NDA”) of Tebipenem HBr, an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis in adults, were insufficient to obtain Food and Drug Administration (“FDA” ) the United States ; (2) as a result, the FDA was unlikely to approve the NDA Tebipenem HBr in its current form; (3) the foregoing would require significant downsizing and restructuring of the Spero Therapeutics business; and (4) therefore, the Company’s public statements were materially false and misleading at all relevant times. When the real details entered the market, the lawsuit claims investors suffered damages.

To join the Spero Therapeutics class action lawsuit, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for class action information.

No class has been certified. Until a class is certified, you are not represented by an attorney unless you retain one. You can choose the lawyer of your choice. You can also remain an absent party member and do nothing at this point. An investor’s ability to participate in any potential future recovery does not depend on their status as lead plaintiff.

Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.

Lawyer advertisement. Previous results do not guarantee a similar result.

See the source version on businesswire.com: https://www.businesswire.com/news/home/20220527005425/en/

CONTACT: Laurence Rosen, Esq.

Phillip Kim, Esq.

The Rosen Law Firm, Pennsylvania

275 Madison Avenue, 40th Floor

New York, NY 10016

Tel: (212) 686-1060

Toll Free: (866) 767-3653

Fax: (212) 202-3827

[email protected]

[email protected]

[email protected]

www.rosenlegal.com

KEYWORD: NEW YORK UNITED STATES NORTH AMERICA

INDUSTRY KEYWORD: PROFESSIONAL LEGAL SERVICES

SOURCE: Rosen Law Firm

Copyright BusinessWire 2022.

PUBLISHED: 05/27/2022 17:20 / DISK: 05/27/2022 17:22

http://www.businesswire.com/news/home/20220527005425/en

Copyright BusinessWire 2022.

Share.

Comments are closed.